Could a 'Cellular Age' test predict lung problems in preemies?

NCT ID NCT03540680

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined whether a marker of cellular aging called p16Ink4a is linked to bronchopulmonary dysplasia (BPD), a serious lung disease in premature babies. Researchers measured p16 levels in blood from 80 newborns and children, comparing those with and without BPD. The goal was to better understand the disease's causes, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help researchers understand why some premature babies develop long-term lung problems and point toward future treatments.

What could go wrong

This is a small, completed observational study that only measures biological markers, not a treatment. It may not lead to any direct medical advances.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, 94000, France